11 ways to play biotech
The Fast Money traders discuss 11 ways to play biotech.
On a sluggish Monday for U.S. stocks, some biotechnology names shined. Celgene and Agios jumped nearly 3 percent while biotech-linked funds continued their steady climbs from last year.Acquisitions and breakthroughs abound in a sector brimming with options ripe for growth. Traders on CNBC’s “Fast Money” outlined their […]
This healthcare edition of Industry Focus takes a look at three biotech stocks and why each company is positioned for a great performance in the coming year.If your portfolio could use some exposure to healthcare and biotechs, join the Fool’s Michael Douglass and Todd Campbell, along with special guest Kristine Harjes, to learn more about three promising stocks in the […]
NASDAQ had a good surge last week, but now people are honestly wondering what’s next. It had a nice pop at the open yesterday,, but immediately headed south and stayed there for the rest of the session. The bad news was that there was no enthusiasm for buying, but the good news was that there was no real selling after […]
Source: Celgene Corp.The volatility that comes with investing in biotech stocks can test the patience of even the most risk-tolerant investor. Many investors may be better served focusing on companies with proven track records of success rather than concentrating on emerging biotech stocks that are more promise than profit. Fortunately, investing in proven performers doesn’t have to mean sacrificing growth! […]
By Ben LevisohnLeerink’s Howard Liang and team think 2015 will be another good year for biotech stocks like Gilead Sciences (GILD), Celgene (CELG), Amgen (AMGN ) and Alexion Pharmaceuticals (ALXN). They explain why:
Boston Globe via Getty Images
Biotech fundamentals appear strong, and could attract and broaden investor interest in the sector. Ongoing and upcoming product launches could be among the fastest […]
To say that biotech stocks have performed well as a group over the last two years is an understatement; they have absolutely crushed the broader markets. For example, the iShares Nasdaq Biotech Index has more than tripled the performance of the S&P 500 , and more than doubled the NASDAQ Composite , since 2012.This sustained move upward, though, has repeatedly […]
Cramer: Celgene has phenomenal pipeline
Mad Money’s Jim Cramer highlights winning biotech names out of the American Society of Hematology Annual Meeting.
As the market licks its wounds from the hideous decline in oil prices, Jim Cramer would like to remind investors that there is one leg of the industry that has no economic sensitivity whatsoever to the price of oil: biotechs. […]
Dividend paying stocks are a staple in market-beating investment portfolios, but dividend investors don’t have very many options when it comes to investing in the biotechnology sector. Out of the largest biotechnology stocks, only Amgen has made the decision to reward investors with dividend payments.That’s likely frustrating to dividend investors. After all, biotech stocks like Gilead Sciences generate billions of […]
It was all about earnings last week with several biotech companies reporting third quarter results. While it was a “beat and raise” quarter for quite a few companies, some companies narrowed their outlooks for the year.Recap of the Week’s Most Important Stories1. Companies like Celgene (CELG – Analyst Report), Biogen (BIIB – Analyst Report), Alexion (ALXN – Analyst Report), Cubist […]
While biotech stocks saw an early selloff Friday, the shares of three companies in the sector have plenty of potential left, John Schroer of Allianz Global Investors said on CNBC.Biogen Idec is his top pick.”Leading company in the [multiple sclerosis] space. They have some very strong earnings growth, 20 to 25 percent earnings growth over the next three years. And […]
